There is increasing evidence that toxicity of mutant superoxide dismutase-1 (SOD1) in amyotrophic lateral sclerosis (ALS) is linked to its propensity to misfold and to aggregate. Immunotargeting of differently folded states of SOD1 has provided therapeutic benefit in mutant SOD1 transgenic mice. The specific region(s) of the SOD1 protein to which these immunization approaches target are, however, unknown. In contrast, we have previously shown, using a specific antibody [SOD1 exposed dimer interface (SEDI) antibody], that the dimer interface of SOD1 is abnormally exposed both in mutant SOD1 transgenic mice and in familial ALS cases associated with mutations in the SOD1 gene (fALS1). Here, we show the beneficial effects of an active immunization strategy using the SEDI antigenic peptide displayed on a branched peptide dendrimer to target monomer/misfolded in SOD1 G37R and SOD1 G93A mutant SOD1 transgenic mice. Immunization delayed disease onset and extended disease duration, with survival times increased by an average of 40 d in SOD1 G37R mice. Importantly, this immunization strategy favored a Th2 immune response, thereby precluding deleterious neuroinflammatory effects. Furthermore, the beneficial effects of immunization correlated with a reduction in accumulation of both monomer/misfolded and oligomeric SOD1 species in the spinal cord, the intended targets of the immunization strategy. Our results support that SOD1 misfolding/aggregation plays a central role in SOD1-linked ALS pathogenesis and identifies monomeric/misfolded SOD1 as a therapeutic target for SOD1-related ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease characterized by the loss of motor neurons from the brain and spinal cord. Approximately 1-2% of ALS cases are caused by mutations in the gene encoding superoxide dismutase-1 (SOD1) (Rosen et al., 1993) , in which Ͼ130 different mutations have now been identified (http://alsod.iop.kcl. ac.uk). There is increasing evidence that the toxicity of mutant SOD1 is linked to its propensity to misfold and to aggregate (Bruijn et al., 2004) . Indeed, aggregated SOD1 is a detectable pathological feature in familial ALS cases caused by mutations in SOD1 (fALS1) and in mutant SOD1 transgenic mice (Bruijn et al., 2004) . Recent reports also suggest that misfolded/aggregated SOD1 may be relevant to cases of sporadic ALS Gruzman et al., 2007; Bosco et al., 2010) . In earlier studies, we described SOD1 exposed dimer interface (SEDI) antibody, which was raised to an epitope within a hydrophobic region normally buried in the native homodimeric structure of SOD1, but is exposed when the dimer is disrupted or becomes monomeric (Rakhit et al., 2007) . As such, SEDI antibody selectively recognizes monomer/misfolded conformations, but not the native structure. Using SEDI antibody, we confirmed the presence of monomer/misfolded SOD1 as a common pathological entity in mutant SOD1 transgenic mice (G37R, G93A, G85R) and in fALS1 (A4V, A4T, I113T, G27/P28, V14M) (Rakhit et al., 2007; Liu et al., 2009) .
Both active and passive immunotargeting of variously folded states of SOD1 has been shown to have therapeutic benefits in mutant SOD1 transgenic mice Gros-Louis et al., 2010; Takeuchi et al., 2010) . For active immunization, recombinant apo-G85R or apo-WT was used as immunogen, based on prior evidence that this metal-free protein had an increased propensity to misfold Takeuchi et al., 2010) . However, this immunogen has epitopes representative of both natively folded and various nondefined misfolded forms of SOD1 Takeuchi et al., 2010) and as such would likely target both native and mutant forms of the protein. For passive immunization, different monoclonal antibodies raised to recombinant G93A and recognizing mutant/misfolded forms of SOD1 were used . Although C4F6 and D3H5 are very interesting antibodies for the study of mutant/misfolded SOD1, the epitopes that they detect currently remain unknown, and as such it is unclear ex-actly what SOD1 species are being targeted. In contrast, the epitope of SEDI antibody is precisely known, amino acid residues 145-151, within the dimer interface of the natively folded SOD1 protein (Rakhit et al., 2007) . We have shown using SEDI antibody that exposure of the dimer interface is common to all SOD1 mutants tested to date, including A4T, A4V, V14M, ⌬G27/P28, G93A, G37R, G85R, and I113T (Rakhit et al., 2007; Liu et al., 2009) , and therefore targeting of this interface may have broad applicability to ALS cases associated with mutations in SOD1. Here, we describe the beneficial effects of using SEDI peptide in an active immunization strategy to specifically target monomer/ misfolded SOD1 in mutant SOD1 transgenic mice.
Materials and Methods
Animal model. Two lines of transgenic mice overexpressing mutant human SOD1 were used in this study. SOD1 G37R mice carrying the human SOD1 gene with a G37R mutation (line 29) were on a pure C57BL/6 background (Wong et al., 1995) . SOD1 G93A mice (B6.Cg-Tg[SOD1-G93A]1Gur/J) purchased from The Jackson Laboratory express a high copy number of the human SOD1 containing the G93A substitution. Both mouse lines were maintained as hemizygotes by breeding transgenic males with C57BL/6 females. Transgenic progeny were identified by PCR using primers specific for human SOD1. All protocols were conducted in accordance with the Canadian Council on Animal Care.
Immunization protocol. SOD1 G37R or SOD1 G93A transgenic mice were immunized intraperitoneally starting at 6 weeks of age. The immunogen used for the study was SEDI peptide designed as a multiple antigenic peptide, with each branch chain consisting of the sequence at the SOD1 dimer interface (residues 143-151) (Rakhit et al., 2007) . One hundred micrograms of SEDI peptide antigen was emulsified 1:1 (v/v) with complete Freund's adjuvant (CFA) for the first immunization, followed by a boost in incomplete Freund's adjuvant at 2 weeks, and once monthly for the next 3 months for SOD1 G37R mice. Two boosts were made after the initial prime for SOD1 G93A mice. Transgenic mice received PBS formulated in CFA followed by incomplete Freund's adjuvant as above for negative controls.
Antibody titers and isotyping. The antibody titer was assayed by ELISA in serum samples collected at 6 months of age and the end stage of disease. Microplates were coated with unfolded SOD1 to determine the antibody titer for mice immunized with SEDI peptide. SOD1 was unfolded overnight at room temperature in Tris-buffered saline, pH 7.4, containing 8 M urea, 2 mM DTT, and 1 mM EDTA (Rakhit et al., 2007) . Serially diluted serum was allowed to bind overnight at 4°C, followed by incubation of HRP-conjugated goat anti-mouse IgG (Pierce). The titer, defined as the dilution yielding 50% of the maximal signal, was detected spectrophotometrically at 405 nm after adding tetramethyl benzene substrate (Pierce). To determine antibody isotype, anti-mouse Ig subclassspecific HRP-conjugated secondary antibodies were added (Zymed Laboratories).
Tissue processing and axon counting. Anesthetized mice were flushperfused transcardially with PBS after CSF was collected. The lumbar segment of spinal cord was removed and processed for paraffin embedding or cryostat sectioning. L5 ventral roots were dissected out and postfixed in formalin. After incubating in 1% osmium tetroxide, roots were dehydrated in graded series of ethanol and embedded in Epon (Marivac). Sections of 1 m were stained with toluidine blue and examined under a light microscope. Motor axons in the cross section of each L5 ventral root were counted, and diameters were determined with stereological microscopy.
Immunohistochemistry and immunofluorescence. Formalin-fixed, paraffin-embedded lumbar spinal cords were cut into 6 m transverse sections. Sections were labeled with hematoxylin and eosin (H&E) or a rabbit polyclonal antibody against glial fibrillary acidic protein (GFAP) (1:1000; Dako). For immunohistochemical detection of activated microglia, formalin-fixed spinal cords were cryoprotected in 30% sucrose in PBS. Ten micrometer cryosections were incubated with a rat monoclonal antibody against Mac-2 (1:100; Cedarlane) followed by biotinylated goat anti-rat IgG (1:200; Vector Laboratories) and biotin-avidin complex conjugated to HRP (1:100; Dako), and visualized with a DAB substrate kit (Vector Laboratories). For double immunofluorescent labeling, freshly dissected lumbar spinal cord was embedded in Tissue-Tek (OCT compound) and frozen in isopentane. Cryosections were incubated with the following antibodies: serum from vaccinated mice (1:100) and GFAP (1:2000; Dako). This was followed by incubation with species-specific secondary antibodies conjugated with Alexa Fluor dye (1:250; Invitrogen). Immunostaining was then visualized by fluorescence microscopy.
Western blotting. For detection of SOD1 oligomers, lumbar spinal cords from the vaccinated mice were prepared in nonreducing conditions as previously described (Furukawa et al., 2006) . Ten micrograms of protein were separated on 12% SDS-PAGE. Following transfer onto PVDF membrane (Millipore), the blot was probed with an antibody to human SOD1 (S100; 1:1000; Nventa Biopharmaceuticals) followed by secondary goat anti-rabbit HRP-conjugated IgG (1:5000; GE Healthcare). Immunoreactivities were developed using ECL reagents (PerkinElmer) and quantified using NIH ImageJ software. The blots were reprobed with a monoclonal anti-GAPDH antibody (1:5000; Biodesign) to show equal loading. To determine whether sera generated from the immunized mice recognized human SOD1 in transgenic mice, spinal cords from nontransgenic (non-Tg) and SOD1 G37R mice were homogenized in RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, and 0.25% Nadeoxycholate). After centrifuging at 15,000 ϫ g for 10 min, supernatants were electrophoresed on 12% SDS-polyacrylamide gels and transferred to PVDF membranes. The membranes were incubated with sera (1:1000) from adjuvant-or SEDI-immunized mice followed by HRP-conjugated secondary antibodies (1:5000) and developed using chemiluminescence. An identical blot was probed with commercial antibodies against human SOD1 (S100; Nventa Biopharmaceuticals) and GAPDH.
Immunoprecipitation. To quantify the level of monomer/misfolded SOD1 in spinal cord of the vaccinated mice, protein extracts were incubated with SEDI antibody and 20 l of 50% (w/v) protein A-agarose (Sigma-Aldrich) in RIPA buffer. Sera obtained from mice immunized with SEDI peptide were used to immunoprecipitate misfolded SOD1 from spinal cord extracts of non-Tg and SOD1 G37R mice. Immunoprecipitates were liberated by boiling in Laemmli sample buffer and analyzed by Western blotting with a polyclonal antibody to SOD1 (1:1000; Calbiochem). A separate blot loaded with 0.3% supernatant input was probed with antibodies to SOD1 (1:1000; Calbiochem) and GAPDH as loading controls.
Behavioral testing. The motor function of transgenic animals was assessed weekly using a rotarod task on an Economex Rotarod instrument (Columbus Instruments). Three trials were performed for each mouse, and the longest time taken to fall was recorded (Azzouz et al., 2004) . Footprint analysis was performed by painting the hindpaws with ink and recording walking patterns (Azzouz et al., 2004 ). An average of four stride lengths were taken for each animal at the time point evaluated.
Statistical analysis. Statistical significance was performed using oneway ANOVA followed by Bonferroni's post hoc test. Kaplan-Meier survival analysis and log rank test were used for disease onset and survival comparisons. Repeated-measures ANOVA were used for rotarod comparisons. A value of p Ͻ 0.05 was considered significant.
Results
Immunization against monomer/misfolded SOD1 improves motor performance, delays disease onset, and extends survival in SOD1 G37R mice To determine whether SOD1 was released into the extracellular space, we tested for the presence of SOD1 in the CSF from mutant SOD1 G37R transgenic mice and non-Tg littermates by Western blot analysis. In agreement with findings in transgenic SOD1 G93A rats (Turner et al., 2005) , both human and endogenous mouse SOD1 was detected in the CSF of SOD1 G37R mice, and mouse SOD1 in the non-Tg animals ( Fig. 1 A) . More importantly, to test for the presence of monomer/misfolded SOD1 in the CSF, immunoprecipitation reactions were performed using the SEDI antibody. Monomeric/misfolded SOD1 was detected in the CSF of SOD1 G37R mice and also of SOD1 G93A mice but not in the non-Tg mice ( Fig. 1 B) , indicating that monomer/misfolded SOD1 as well as natively folded SOD1 is present extracellularly as well as intracellularly.
In vitro studies have shown that mutant forms of SOD1 have a higher propensity to misfold and/or to dissociate into monomers and ultimately aggregate ( . We therefore evaluated the therapeutic benefits of an active immunization approach using SEDI peptide to specifically target monomer/misfolded SOD1. SOD1 G37R mice were immunized with SEDI peptide (n ϭ 10) in CFA, using PBS in CFA (saline-CFA) as negative control (n ϭ 10), from 6 weeks of age until 5 months of age. Immunization was initiated at 6 weeks of age to determine the effect of removing monomer/misfolded SOD1 on timing of disease onset. Second, immunization at an early stage would prevent potential conflicts with the neuroinflammatory contribution to the disease that is typically observed after disease onset. All treated animals were subjected to rotarod testing to analyze the effects of immunization on motor function. SOD1 G37R mice injected with saline-CFA showed a significant decline on the rotarod task at 323 d, and motor function continued to decline as disease progressed (Fig. 1C) . In contrast, motor performance was significantly improved in SEDI peptide-immunized mice over the course of disease compared with mice injected with saline-CFA (Fig. 1C) . Footprint analyses using hindlimb stride length as an index of motor function was also performed. Mice vaccinated with SEDI peptide had significant improvements in walking patterns compared with controls ( Fig.  1D ,E). Mice were monitored for disease onset, as defined by a 20% reduction in rotarod performance. Saline-CFA-injected mice showed an onset of motor deficits at 325.7 Ϯ 3.0 d, while the onset of motor deficits was significantly delayed to 353.2 Ϯ 3.7 d (p Ͻ 0.0001) in mice immunized with SEDI peptide (Fig. 1F) . Clinical end stage was defined as the age when the mouse was unable to right itself within 30 s after being placed on its side. Animals receiving SEDI peptide immunization showed a significant increase in life span compared with those receiving saline-CFA (392.5 Ϯ 3.6 vs 352.1 Ϯ 1.9 d; p Ͻ 0.0001; Fig. 1G ). Furthermore, immunization slowed disease progression as the duration of the disease in SEDI peptide was 39.3 d compared with 26.4 d for saline-CFAinjected mice.
Immunization with SEDI peptide generates anti-SOD1 antibody and Th2-biased immune response
To assess the anti-SOD1 immune responses elicited by SEDI peptide, we determined the antibody titers from the collected serum samples of immunized mice at 6 months of age and disease end stage. At 6 months of age, low-titer antibodies to unfolded SOD1 were observed in animals immunized with SEDI peptide (319 Ϯ 40; n ϭ 10; Fig. 2 A) . An increase in antibody titer in immunization with SEDI peptide (605 Ϯ 37; n ϭ 10) was detected at end stage (Fig.  2 A) . Animals receiving saline-CFA had negligible SOD1 titers at G37R transgenic mice and nontransgenic littermates probed with commercially available SOD1 antibody (Calbiochem). Both the mouse wild-type SOD1 protein and the human SOD1 G37R protein were detected in CSF. B, Composite immunoblot probed with commercially available SOD1 antibody (Calbiochem) showing monomer/misfolded SOD1 protein immunoprecipitated from CSF of SOD1 G37R and SOD1 G93A transgenic mice in comparison with non-Tg. This shows that monomer/misfolded SOD1 is present extracellularly in mutant SOD1 transgenic mice. Rotarod task (C) and footprint analysis (D) were performed to evaluate motor deficits in immunized mice. Mice immunized with SEDI peptide (black; n ϭ 10) showed significant improvement in rotarod task and in stride length compared with CFA-treated mice (gray; n ϭ 9). Values are expressed as mean Ϯ SEM (*p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001). E, Representative footprints from CFA-and SEDI peptide-immunized animals at 340 d of age. Age of disease onset (F ) and survival (G) in SOD1 G37R mice immunized with CFA (gray; n ϭ 9) and SEDI peptide (black; n ϭ 10). Immunization with SEDI peptide significantly delayed disease onset and prolonged life span. both 6 months of age (18 Ϯ 6; n ϭ 10) and end stage (24 Ϯ 9; n ϭ 10; Fig. 2 A) .
To further characterize the antibody response, we determined the IgG isotype, the profile of which is influenced by the Th1/Th2 balance of the immune system. Th1 response produces proinflammatory cytokines and is critical in cell-mediated immunity, while Th2 response stimulates antibody production and plays an important role in humoral immunity. The ratio of IgG1 to IgG2a antibodies produced serves as an indirect measurement of Th2-and Th1-type of immune response (Finkelman et al., 1990) . All mice immunized with SEDI peptide generated IgG1 antibodies and negligible levels of IgG2a (data not shown). The ratio of IgG1 to IgG2a exceeded 1 after immunization with SEDI peptide (1.25 Ϯ 0.08; n ϭ 10), indicating a predominance of Th2-biased immune response. To test whether IgG was present in the spinal cord of immunized mice, frozen transverse sections from immunized and nonimmunized animals were labeled with Alexa Fluor 488 goat anti-mouse secondary antibody. Labeling of motor neurons within the ventral horn was clearly apparent in immunized animals but not in nonimmunized mice (Fig. 2 B, arrows) .
Induced SOD1 antibodies recognize SOD1 in ALS transgenic mice
To determine specificity of sera to pathologically relevant features in ALS mouse models, the immunoreactivity of actively generated sera was tested against disease tissue of untreated transgenic mice. No labeling was detected with sera from control mice (Fig. 3A-D) , whereas a diffuse pattern of monomer/misfolded SOD1 with sera from SEDI peptide-immunized mice in motor neuron perikarya and neurites was detected (Fig. 3G,H, arrows) . Interestingly, immunoreactivity to the SEDI epitope was also found in neighboring astrocytes, an observation we have made previously (Rakhit et al., 2007) . Double labeling with SEDI peptide-immunized sera and GFAP, a marker for astrocytes, confirmed the presence of monomer/misfolded SOD1 in astrocytes (Fig. 3E-G) . Detection of SOD1 with sera from vaccinated mice was confirmed by Western blotting (Fig. 3I ) . The presence of monomer/misfolded SOD1 in spinal cord lysates was detected by immunoprecipitation using sera from mice immunized with SEDI peptide and then immunoblotting with SOD1 antibody (Calbiochem) (Fig. 3I ) . In contrast, no SOD1 immunoreactivity was observed with sera from saline-CFA-injected mice (Fig. 3I ) .
Immunization with SEDI peptide protects motor neurons and reduces gliosis
To correlate the behavioral improvement with pathological outcome measures, the effect of immunization on the size and number of motor axons in L5 ventral roots was quantified. At disease onset (320 d), we observed a 50% reduction in the total number of motor axons in saline-CFA-injected mice (444 Ϯ 23; n ϭ 4; p Ͻ 0.001; Fig. 4 A) compared with non-Tg mice (951 Ϯ 69; n ϭ 4; Fig. 4C ), whereas motor axons at the same time point in mice vaccinated with SEDI peptide (Fig. 4 B) were well preserved and their number was statistically indistinguishable from non-Tg mice (853 Ϯ 51 in mice receiving SEDI peptide, n ϭ 4, p Ͼ 0.05, vs 951 Ϯ 69 in non-Tg mice, n ϭ 4). Further analyses showed that immunization with SEDI peptide protected large motor neurons. Average counts of large motor axons (Ͼ5 m) in SEDI peptideimmunized (711 Ϯ 64; n ϭ 4; p Ͼ 0.05) animals were similar to non-Tg animals (813 Ϯ 76); in contrast, animals receiving saline-CFA showed a 63% loss of large motor axons (293 Ϯ 32 vs 813 Ϯ 76; n ϭ 4; p Ͻ 0.001; Fig. 4 D) .
Immunohistochemical analysis of the lumbar spinal cord also showed a substantial loss of motor neurons in CFA-treated mice as shown by H&E labeling (Fig. 4 E) . Similarly to the preservation of motor axons, more intact and healthy motor neurons were found in mice immunized with SEDI peptide (Fig. 4 H) . In ALS, loss of motor neurons is accompanied by a robust inflammatory response. The cellular events consist of proliferation and activation of astrocytes and microglia at the sites of degenerating motor neurons (McGeer and McGeer, 2002; Sargsyan et al., 2005) . In mutant SOD1 transgenic mice, it is well documented that activation of microglia is evident at presymptomatic stage, and astrogliosis is prominent at disease onset (Hall et al., 1998; Alexianu et al., 2001; McGeer and McGeer, 2002) . To probe the effect of immunization on glial responses at disease onset (320 d), lumbar spinal cord sections from immunized mice were labeled for GFAP and Mac-2, as markers for astrogliosis and activated microglia, respectively. Consistent with previous reports, we observed intense astrogliosis and microglial activation as shown by strong immunolabeling of GFAP and Mac-2, respectively, in saline-CFA-treated mice (Fig. 4 F, G) . However, in mice vaccinated with SEDI peptide (Fig. 4 I, J ) , immunoreactivity of GFAP and Mac-2 was greatly attenuated. These results indicate that immunization with SEDI peptide not only delays degeneration of motor neurons but also reduced associated astrogliosis and microglial activation.
Effects of SEDI peptide immunization in SOD1
G93A transgenic mice SOD1 G93A transgenic mice overexpressing ϳ20 copies of the mutant gene are the most widely used animal model for testing therapeutic strategies and studying disease mechanisms in ALS. Therefore, we also assessed the effect of immunization with SEDI peptide in SOD1 G93A mice, an early-onset ALS mouse model (Gurney et al., 1994) . Immunization was initiated at 6 weeks of age followed by a boost at 8 weeks of age and a final boost at 12 weeks of age. Both rotarod and footprint analyses were conducted weekly to evaluate motor performance. A significant decline in rotarod performance was detected in saline-CFA-injected mice at 117 d that progressively became worse over the course of disease (Fig. 5A) . Improvements in rotarod performance (119 -126 d; p Ͻ 0.05; Fig. 5A ) and stride length (130 d; p Ͻ 0.001; Fig.  5B) were not found to be statistically significant in mice immunized with SEDI peptide. A 12 d delay in disease onset was observed in mice vaccinated with SEDI peptide (129.6 Ϯ 3.8 vs 117.2 Ϯ 1.4 d; p ϭ 0.0005; Fig. 5C ); however, this did not translate to an significant increase in life span (165.5 Ϯ 3.1 vs 158.6 Ϯ 2.7 d; p ϭ 0.0528; Fig. 5D ).
SEDI peptide immunization reduces monomer/misfolded and oligomeric SOD1
We further explored the molecular mechanisms mediating the therapeutic effects of SOD1 immunization. Studies have shown that mutant SOD1 forms aggregates in vitro (Rakhit et (Johnston et al., 2000; Wang et al., 2002; Furukawa et al., 2006) . Therefore, the improvement of motor function and mortality may stem from the reduction of oligomeric/aggregated SOD1 species. To address this, we measured the presence of high-molecular-weight SOD1 oligomers by immunoblot analyses. In mice receiving saline-CFA, SOD1 oligomers were found in lumbar spinal cord extracts at 320 d (Fig.  6 A) . In contrast, immunization with SEDI peptide reduced the accumulation of SOD1 oligomers by 92.6 Ϯ 24.6% (n ϭ 4; p Ͻ 0.01) compared with the level in control mice (Fig. 6 A) . Using SEDI antibody to immunoprecipitate monomer/mis- G37R and non-Tg mice were subjected to immunoprecipitation using antisera from mice immunized with SEDI peptide (mouse ID 544 and 551) or saline-CFA (mouse ID 594 and 596). The immunoprecipitates were then probed by Western blot using SOD1 antibody (Calbiochem). Note that antisera from SEDI peptide-immunized animals immunoprecipitated monomer/misfolded SOD1 from SOD1 G37R mice but not non-Tg mice, and that no signal was detected using antisera from saline-CFA-immunized animals. A separate immunoblot of the spinal cord lysates used as input for the immunoprecipitations shows the presence of human and/or mouse SOD1 in the SOD1 G37R or non-Tg mice, respectively, with GAPDH used as the loading control.
folded SOD1, we found a 35.2 Ϯ 6.5% (n ϭ 4; p Ͻ 0.05) decrease in monomer/ misfolded SOD1 after immunization with SEDI peptide compared with control (Fig. 6 B) .
Discussion
Although previous immunization studies have targeted pathological forms of SOD1 in mutant SOD1 transgenic mice, the precise epitopes targeted are unknown Gros-Louis et al., 2010; Takeuchi et al., 2010) . Here, we have used SEDI peptide in an immunization strategy to specifically target monomer/misfolded SOD1 species in which the dimer interface is exposed (Rakhit et al., 2007) . The therapeutic benefits of this strategy included a delay in disease onset, extension of disease progression, and prolongation of survival by up to 40 d. Importantly the SEDI peptide antigen directed a Th2-biased immune response, and this led to a reduction in monomer/misfolded SOD1, the intended target of the immunization strategy. This provides the first evidence for the neurotoxicity of monomeric/misfolded SOD1 in vivo and validates these species as legitimate therapeutic targets for the treatment of SOD1 associated ALS. There are Ͼ130 different mutations found in the SOD1 gene in ALS (http:// alsod.iop.kcl.ac.uk). The mode of toxicity of the different mutations is thought to be through induction of misfolding and/or aggregation of the mutant SOD1 protein as an upstream event leading to a multipathway neurodegenerative cascade that causes motor neuron degeneration, as well as the accompanying pathological changes, such as gliosis, that are typically associated with ALS. Mutations in SOD1 have been shown to promote SOD1 misfolding/aggregation through at least three distinct mechanisms: reducing the net charge, impairing metal binding, or destabilizing the native structure (DiDonato et al., 2003; Khare et al., 2004; Leinweber et al., 2004; Stathopulos et al., 2006; Shaw and Valentine, 2007) . In vitro aggregation assays of SOD1 have identified a multistep process in which the SOD1 dimer is destabilized, forming a monomeric species before the formation of aggregates (Rakhit et al., 2002 (Rakhit et al., , 2004 Khare et al., 2004) . Evidence for this mechanism in vivo was shown using the SEDI antibody, which detected monomeric/misfolded SOD1 in three lines of mutant SOD1 transgenic mice (G37R, G85R, and G93A) and in five different human fALS1 cases (A4T, A4V, V14M, ⌬G27/P28, and I113T) (Rakhit et al., 2007; Liu et al., 2009) , indicating that there is a common misfolding pathway among the different SOD1 mutant proteins in vivo. In this regard, we used SEDI peptide as antigen in an immunization strategy aimed at specifically targeting this common misfolded species, monomer/misfolded SOD1, in mutant SOD1 transgenic mice. Induced antibody titers were detectable at 6 months of age in the immunized SOD1 G37R mice and increased approximately twofold by ϳ10 months of age. Sera from mice immunized with SEDI peptide labeled SOD1 aggregates in diseased spinal motor neurons and gave no labeling of control nontransgenic mouse spinal cord. Furthermore, sera from the SEDI-immunized animals immunoprecipitated monomeric/misfolded SOD1 from diseased tissue, confirming the selectivity of the induced antisera for pathological SOD1. Importantly, immunization with SEDI peptide directed a Th2-biased immune response, which promotes antibody production and suppresses the Th1-type proinflammatory response. Of note, it was a Th1 immune response that led to meningoencephalitis in a subset of patients receiving immunizations of A␤ peptide in the AN1792 clinical trial for Alzheimer's disease (for review, see -González et al., 2011) . Interestingly, Urushitani and colleagues (Takeuchi et al., 2010) have shown that immunization with WT-apo SOD1 induces a higher Th2/Th1 milieu than G93A-apo SOD1 vaccination, indicating the importance of antigen selection in obtaining the desired outcomes. In this regard, here we have shown that SEDI peptide gave a favorable Th2-biased immune response.
Menéndez
The therapeutic targeting of monomer/misfolded SOD1 delayed disease onset by an average of 25 d in SOD1 G37R transgenic mice, further implying that these species contribute to the earliest stages of disease. SEDI peptide immunization also delayed disease onset by 12 d in the SOD1 G93A transgenic mice, which was not observed when recombinant mutant SOD1 protein was used as immunogen , perhaps suggesting that SEDI peptide is a more efficacious immunogen, at least in this system. Immunization with SEDI peptide not only protected motor neurons, the primary target of SOD1 toxicity, but also reduced neuroinflammatory responses including astrogliosis and microgliosis, implying that these events are downstream from the generation of monomer/misfolded SOD1. Non-cell-autonomous toxicity is well documented in transgenic SOD1 mice (Clement et al., 2003; Beers et al., 2006; Boillée et al., 2006) . Suppression of inflammatory responses has had various effects primarily on disease duration in mutant SOD1 transgenic mice (Kriz et al., 2002; Zhu et al., 2002; Klivenyi et al., 2004) , and by extension our results show that amelioration of astrogliosis and microgliosis also correlates with a lengthening of disease duration. The preferential Th2 immune response in our immunization study may also have contributed to the reduced inflammatory responses. Significantly, monomer/ misfolded SOD1 was detected in the CSF of mutant SOD1 transgenic mice, and based on earlier studies describing the neurotoxicity of extracellular SOD1 either directly or through activation of glial cells , a potential mechanism of the immunization strategy is to clear misfolded SOD1 from the extracellular milieu. In this regard, although a number of theories have been promulgated for the mechanistic action of immunization for the treatment various neurodegenerative diseases (Masliah et al., 2005; Asuni et al., 2007; Urushitani et al., 2007; Takeuchi et al., 2010) , as with these earlier studies, we were also unable to ascertain which pools of monomer/misfolded SOD1 our immunization strategy targeted, extracellular or intracellular. It is possible that there is Fc receptor-mediated phagocytosis of SOD1/antibody complexes by microglia, as shown in animal models of Alzheimer's disease (Bard et al., 2000) . As mentioned, the presence of misfolded SOD1 in the CSF would be consistent with this mode of action. The clearance of intracellular SOD1 aggregates might involve the entrance of anti-SOD1 antibodies into motor neurons. Supporting evidence for this mechanism came from reports that IgG can be taken up by motor neuron terminals and transported retrogradely to the cell body (Fabian and Petroff, 1987; Mohamed et al., 2002) . Indeed, IgG reactivity was found in motor neurons in the spinal cord of ALS cases (Engelhardt and Appel, 1990) , and we detected IgG within motor neuron perikarya of immunized mice. Internalized antibodies may exert an inhibitory effect on SOD1 aggregation and/or trigger the endosomal/lysosomal pathway, as has been described previously (Masliah et G93A CFA-treated mice (black; n ϭ 9) and SEDI peptide (gray; n ϭ 10)-immunized mice. Immunization with SEDI peptide significantly delayed disease onset but did not significantly prolong survival. Importantly, we ascertained using immunoprecipitation studies from spinal cord that there was an overall reduction in the amount of monomer/misfolded SOD1 in SEDI peptideimmunized animals relative to controls, the intended target of the immunization strategy. We also found a reduction in highermolecular-weight oligomeric SOD1 species. It appears from these results that monomer/misfolded SOD1 is a precursor required to form the higher-molecular-weight oligomeric SOD1 species. We were unable to ascertain from our results whether it is the monomer/misfolded SOD1 itself that is the toxic entity, or whether it is the oligomeric species that are toxic, and this is part of an ongoing study. SEDI peptide immunization prolonged survival of SOD1 G37R transgenic mice by an average of 40 d, and although this may seem modest for an animal model exhibiting an average life span of 325 d, it should be borne in mind that only small amounts of antibody cross the blood-brain barrier [ϳ0.1% of serum levels (Bard et al., 2000) ], which is likely to be insufficient to counter the fivefold overexpression of the mutant SOD1 protein in the SOD1 G37R mice. This is supported by the fact that, although immunization modestly delayed disease onset in the SOD1 G93A transgenic mouse in which there is a ϳ20-fold overexpression of mutant SOD1, there was no prolongation of survival. Furthermore, there may be additional pathological SOD1 species, not targeted by our immunization strategy, that also contribute to the pathogenic process Bosco et al., 2010; Gros-Louis et al., 2010; Takeuchi et al., 2010; Pokrishevsky et al., 2012) . In this regard, there is evidence that C4F6 antibody labels "mal-folded" forms of SOD1 in transfected cell lines (Prudencio and Borchelt, 2011) , and a series of peptide antibodies have been produced that detect chemically denatured non-native forms of SOD1 (Forsberg et al., 2010) . Both sets of antibodies have been reported to label diffuse and/or small punctate-like SOD1 inclusions of 0.5-3 m in sporadic ALS (Bosco et al., 2010; Forsberg et al., 2010) , although recently it was reported that labeling is also obtained using C4F6 antibody in control tissues (Brotherton et al., 2012) . In contrast, SEDI antibody appears specific for fALS1 mutant SOD1 and has been verified as labeling all SOD1 mutants tested to date in both fALS1 cases (A4V, A4T, I113T, G27/P28, V14M), labeling the characteristic hyaline conglomerate inclusions (Hays, 2006; Hays et al., 2006) , and in mutant SOD1 transgenic mice (G37R, G93A, G85R) (Liu et al., 2009) , and this strengthens the argument for targeting monomer/misfolded SOD1 therapeutically in fALS1 cases.
The immunization strategy that we propose here is aimed at removing monomer/misfolded SOD1 as it is produced to ameliorate the disease. Another strategy currently undergoing clinical trials is antisense oligonucleotide therapy. In this approach, expression of the mutant gene is downregulated by the targeted antisense oligonucleotide (AON), reducing the total amount of mutant SOD1 protein generated (Smith et al., 2006) . Although more invasive than immunization, this approach holds great promise and may prove to be most effective when administered before disease onset. However, it is also likely that some mutant SOD1 protein will continue to be generated, escaping the effect of the AON and form toxic monomer/misfolded SOD1. In this case, AON could be combined with an immunization strategy to remove monomer/misfolded SOD1 as a "second hit" to effectively treat the disease. Importantly, there is increasing evidence that propagation of neurodegenerative diseases, including ALS, are propagated by the cell-cell transmissibility of pathological misfolded proteins (Grad et al., 2011; Prudencio and Borchelt, 2011; de Calignon et al., 2012) . We have shown here that monomer/ misfolded SOD1 is present within the extracellular milieu, and as such, SEDI peptide immunization could be important to halting or slowing the progression of the disease by preventing cell-cell transmissibility of monomer/misfolded of SOD1.
In summary, our findings show that an immunotherapeutic approach specifically targeting monomer/misfolded SOD1 ameliorates disease phenotype and pathology in mutant SOD1 transgenic mice. These findings not only indicate the pathogenic nature of these species but also identify monomer/misfolded SOD1 as a valid therapeutic target for the treatment of ALS.
